Apremilast for the treatment of psoriasis and psoriatic arthritis

Chaplin, Steve MSc, BPharm

¹a pharmacist who specialises in writing about therapeutics

Future Prescriber 14(1):p 8-9, July 2013.

Apremilast, an orally active inhibitor of phosphodiesterase 4 that inhibits several inflammatory cytokines, is being developed for the treatment of psoriasis and psoriatic arthritis. This Drug profile reviews the clinical data to date.